Prostvac
Prostvac is an investigational immunotherapy for the treatment of prostate cancer. It is being developed by Bavarian Nordic, a biotechnology company specializing in vaccines.
Overview[edit]
Prostvac uses a virus as a vector to deliver antigens to the immune system. The antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.
Clinical Trials[edit]
Prostvac has been tested in several clinical trials. In a Phase II trial, Prostvac was shown to extend the median survival of patients with metastatic castration-resistant prostate cancer by 8.5 months compared to a placebo. However, a subsequent Phase III trial did not meet its primary endpoint of improving overall survival.
Mechanism of Action[edit]
Prostvac works by stimulating the body's immune system to attack prostate cancer cells. It does this by using a virus to deliver antigens to the immune system. These antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.
Side Effects[edit]
The most common side effects of Prostvac are flu-like symptoms, including fever, chills, and fatigue. These symptoms are typically mild and temporary.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
